Advertisement

Can immunotherapy treat skin cancer?

Learn how cutting-edge medications called immune checkpoint inhibitors may be used for difficult-to-treat skin cancers.

Medical icons on wooden blocks.

Updated on April 4, 2025

Immunotherapy is a category of cancer treatment that helps the body’s natural immune system attack and destroy cancer. It has been called the “fourth pillar” of cancer treatment. The other three pillars are considered to be chemotherapy, surgery, and radiation therapy.

Although they are a relatively recent development in cancer treatment, numerous immunotherapy drugs are being used to treat a variety of cancers, including skin cancers like advanced basal cell carcinoma, advanced squamous cell carcinoma, and melanoma. 

Cancer and the immune system

One of the main functions of the immune system is to rid the body of things that don’t belong, such as harmful bacteria, viruses, parasites, damaged cells, and cells that have mutated (like cancer cells). To do this, the immune system creates antibodies that attack and destroy things that are abnormal.

To protect normal, healthy cells from antibodies, the body uses something called immune checkpoints. These are proteins that signal the immune system not to attack certain cells.

Some cancerous cells—including some skin cancer cells—use immune checkpoints to remain undetected. This allows the cancer to continue to grow and divide without being attacked by the immune system.

Immune checkpoint inhibitors

The immunotherapy drugs used in the treatment of skin cancer are called immune checkpoint inhibitors. These drugs work by disabling immune checkpoints, which allows the immune system to identify and attack cancerous cells.

Immune checkpoint inhibitors are typically used for advanced skin cancers, skin cancers that have spread to other sites in the body, and/or skin cancers that cannot be treated with surgery.

Different immune checkpoint inhibitors are indicated for different types of skin cancer:

Basal cell carcinoma (BCC)

Basal cell carcinoma is the most common form of skin cancer. The first immune checkpoint inhibitor indicated for the treatment of basal cell carcinoma was approved by the FDA in February 2021. It is used to treat advanced basal cell carcinoma that has not responded to other medications.

Squamous cell carcinoma (SCC)

Squamous cell carcinoma is the second-most common form of skin cancer. There are two immune checkpoint inhibitors that can be used in the treatment of advanced squamous cell carcinoma when surgery and/or radiation therapy are not appropriate treatment options.

Melanoma

Melanoma is less common than basal cell carcinoma and squamous cell carcinoma, but it is more likely to spread. There are four immune checkpoint inhibitors approved for the treatment of melanoma, which target different checkpoints. These are used in cases where the melanoma cannot be treated by surgery or has metastasized (spread to other sites in the body). Some are also used as adjuvant treatments—therapies that help prevent a recurrence or relapse of cancer.

Merkel cell carcinoma

Immune checkpoint inhibitors may also be used in the treatment of this rare-but-aggressive form of skin cancer, usually when the cancer has spread.

Work with your healthcare team

It is important to remember that not every treatment is right for every person, and that every case of skin cancer is different. Like other cancer treatments, immunotherapy drugs cause side effects. A person should work with their healthcare team to understand the potential risks and benefits before starting any treatment.

Article sources open article sources

Hunter P. The fourth pillar: Despite some setbacks in the clinic, immunotherapy has made notable progress toward becoming an additional therapeutic option against cancer. EMBO Rep. 2017 Nov;18(11):1889-1892.
American Cancer Society. Immunotherapy for Advanced Basal or Squamous Cell Skin Cancers. December 16, 2024.
American Cancer Society. Immunotherapy for Melanoma Skin Cancer. September 19, 2024.
Cancer Research UK. The immune system and cancer. November 6, 2023.
National Cancer Institute. Immune Checkpoint Inhibitors. April 7, 2022.
NCI Dictionary. Immune checkpoint inhibitor. Accessed April 4, 2025.
American Academy of Dermatology Association. Types of Skin Cancer. Accessed April 4, 2025.
U.S. Food & Drug Administration. FDA approves cemiplimab-rwlc for locally advanced and metastatic basal cell carcinoma. February 9, 2021.
Skin Cancer Foundation. Melanoma Overview. Accessed April 4, 2025.
American Cancer Society. Targeted Therapy Drugs for Melanoma Skin Cancer. October 27, 2023.
American Academy of Dermatology Association. Skin Cancer Types: Merkel Cell Carcinoma Diagnosis & Treatment. Accessed April 4, 2025.
Elsevier Point of Care. Clinical Overview: Merkel cell cancer.

Featured Content

article

Treating melanoma with subcutaneous immunotherapy

How injections of subcutaneous immunotherapy are being used in the treatment of melanoma skin cancers.